Canada - français - Health Canada

biontech manufacturing gmbh - tozinaméran - suspension - 30mcg - tozinaméran 30mcg

Canada - français - Health Canada

biontech manufacturing gmbh - tozinaméran - suspension - 10mcg - tozinaméran 10mcg

Canada - français - Health Canada

biontech manufacturing gmbh - tozinaméran - suspension - 30mcg - tozinaméran 30mcg

Canada - français - Health Canada

biontech manufacturing gmbh - tozinaméran - suspension - 3mcg - tozinaméran 3mcg

Union européenne - français - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles.

Canada - français - Health Canada

biontech manufacturing gmbh - tozinaméran; famtozinamÉran - suspension - 15mcg; 15mcg - tozinaméran 15mcg; famtozinamÉran 15mcg

Canada - français - Health Canada

biontech manufacturing gmbh - tozinaméran; famtozinamÉran - suspension - 5mcg; 5mcg - tozinaméran 5mcg; famtozinamÉran 5mcg

Union européenne - français - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - l'antithrombine alfa - déficit en antithrombine iii - agents antithrombotiques - atryn est indiqué pour la prophylaxie de la thromboembolie veineuse dans la chirurgie des patients présentant un déficit congénital en antithrombine. atryn est normalement administré en association avec de l'héparine ou de l'héparine de bas poids moléculaire.

Canada - français - Health Canada

biontech manufacturing gmbh - tozinaméran; riltozinamÉran - suspension - 15mcg; 15mcg - tozinaméran 15mcg; riltozinamÉran 15mcg

Canada - français - Health Canada

biontech manufacturing gmbh - raxtozinaméran - suspension - 30mcg - raxtozinaméran 30mcg